A retrospective study followed the clinical outcomes of 142 non-small cell lung cancer patients who started anti-PD-1/PD-L1 immunotherapy between January 2016 and January 2018 (83). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.